[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital of Ningbo University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":388},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,40,64,93,115,148,176,197,223,244,265,296,321,344,365],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100595317","effect-of-spacer-use-on-exacerbation-risk-in-high-risk-older-adults-with-chronic-airway-diseases-receiving-triple-therapy-100595317",false,"NCT07030881","Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥65 years, no gender restriction;\n2. Confirmed diagnosis of chronic obstructive pulmonary disease (COPD) based on GOLD criteria or bronchial asthma based on GINA criteria;\n3. Currently on stable treatment with fixed-dose combination ICS\u002FLABA\u002FLAMA via pMDI for ≥4 weeks;\n4. History of any of the following in the past 12 months:\n\n   1. ≥1 hospitalization due to exacerbation, or\n   2. ≥2 moderate exacerbations requiring systemic corticosteroids and\u002For antibiotics;\n5. Able to complete inhalation technique training and demonstrate basic communication and device-handling abilities;\n6. Provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Use of other inhalation devices as primary therapy (e.g., DPI, SMI, or nebulizer);\n2. Regular use of a spacer device for ≥3 weeks within 3 months prior to enrollment;\n3. Current or recent (within 4 weeks) acute exacerbation not fully resolved;\n4. Severe cognitive impairment (MMSE score \\\u003C18);\n5. Presence of severe systemic comorbidities (e.g., end-stage malignancy, advanced heart failure, hepatic or renal failure);\n6. Participation in another interventional clinical trial;\n7. Inability to use a mouthpiece-based spacer (e.g., structural oral\u002Ffacial abnormalities, severe anxiety);\n8. Known allergy or hypersensitivity to spacer device materials.","ALL","65 Years",{"count":19,"type":20},380,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study evaluates whether adding a spacer device to triple inhaled therapy (ICS\u002FLABA\u002FLAMA via pMDI) can reduce acute exacerbations in elderly patients (≥65 years) with stable chronic airway diseases (COPD or asthma) who are classified as high-risk based on GOLD or GINA guidelines. High risk is defined as ≥1 hospitalization or ≥2 moderate exacerbations in the past 12 months.\n\nDespite receiving triple inhaled therapy, these patients often have poor inhaler technique due to age-related limitations. A spacer may improve drug delivery, adherence, and reduce local side effects.\n\nIn this multicenter, open-label, randomized controlled trial, 380 participants will be assigned to standard therapy with or without a valved spacer. The primary outcome is the 3-month incidence of moderate-to-severe exacerbations. Secondary outcomes include lung function, adherence, inhalation technique, side effects, and patient satisfaction.",[26],"Asthma, COPD","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":31},"2025-06-17",{"date":35,"type":20},"2027-06-30",{"name":37,"class":38},"First Affiliated Hospital of Ningbo University","NETWORK",9,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":62,"locationsCount":63},"100572351","remote-anxiety-management-for-ics-resistant-asthma-study-100572351","NCT06732141","Remote Anxiety Management for ICS-resistant Asthma Study","Remote Management Strategies and Adherence Improvement for Anxiety-related ICS Resistance in Asthma Patients: an Open-label, Multicenter, Randomized Controlled Trial","RAMICS","Inclusion Criteria:\n\n1. Age Requirement:\n\n   Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions.\n2. Diagnosed Asthma:\n\n   1. Diagnosis must meet the criteria of the Global Initiative for Asthma (GINA) or the American Academy of Asthma guidelines, with at least one confirmed diagnosis by a specialist in the past six months.\n   2. Asthma severity must range from mild to moderate persistent, in the chronic management phase, excluding patients in acute exacerbation phases for clearer evaluation of adherence and intervention effects.\n3. ICS Treatment History:\n\n   1. Participants must have been on inhaled corticosteroid (ICS) therapy for at least six months, ensuring sufficient treatment history for adherence and effect evaluation.\n   2. No major changes to asthma control medication regimen in the past six months, ensuring adherence and intervention outcomes are not confounded by treatment changes.\n4. Poor Medication Adherence:\n\n   Identified using the Medication Adherence Report Scale (MARS-10), with an average score \\\u003C4.5, indicating suboptimal adherence.\n5. Presence of Anxiety Symptoms:\n\n   1. Confirmed through the Hamilton Anxiety Rating Scale (HAMA), with a score ≥14, indicating clinically significant anxiety.\n   2. Anxiety symptoms must be related to asthma treatment, particularly concerns about ICS side effects or long-term use, ensuring the psychological intervention targets relevant issues.\n6. Ability to Communicate by Phone:\n\n   Participants must have stable access to a phone and be willing to engage in telephone-based psychological interventions.\n7. Stable Health Condition:\n\nAsthma status must be stable, with no acute exacerbations or significant changes in the past month.\n\nExclusion Criteria:\n\n1. Severe Psychiatric or Cognitive Disorders:\n\n   1. Diagnosis of major psychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, or other severe mental illnesses within the past six months, based on DSM-5 criteria.\n   2. Presence of cognitive impairments or neurological conditions, such as dementia or post-stroke complications, that may affect comprehension or adherence to the intervention.\n   3. Current psychiatric treatment involving antipsychotics, antidepressants, or sedatives that could interfere with the intervention's outcomes.\n2. Substance Abuse or Dependence:\n\n   History of alcohol or drug abuse within the past six months, including but not limited to opioids, benzodiazepines, or illicit substances.\n3. Severe Comorbidities:\n\n   1. Uncontrolled respiratory or cardiovascular conditions, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, heart failure, or uncontrolled hypertension, that could significantly impact asthma control and overall health.\n   2. Chronic diseases requiring long-term systemic corticosteroid therapy, such as rheumatic or autoimmune diseases, that may interfere with ICS treatment and study outcomes.\n4. Pregnancy or Lactation:\n\n   Pregnant or breastfeeding women are excluded due to the unclear risks of ICS treatment and anxiety management interventions in these populations.\n5. Allergic Bronchopulmonary Aspergillosis (ABPA) or Related Conditions:\n\n   Diagnosed ABPA or other respiratory diseases with mechanisms distinct from asthma, which could confound the assessment of ICS treatment effects.\n6. Participation in Other Interventional Clinical Trials:\n\n   Participation in another interventional clinical trial within the past three months, particularly those involving respiratory diseases or medication adherence management, to avoid confounding effects on outcomes.\n7. Incompatibility with Telephone-Based Interventions:\n\n   Inability to reliably receive or engage in telephone-based psychological interventions due to hearing impairments, communication barriers, or other reasons.\n8. Adverse Reactions to Psychological Interventions:\n\n   Documented refusal of or adverse reactions to psychological interventions, such as phone-based relaxation or motivational interviewing, that could affect the feasibility and effectiveness of the study.\n9. History of Major Surgery or Hospitalization:\n\nHistory of major surgery or hospitalization (unrelated to asthma) within the past six months that might impact current health status and introduce bias into the study outcomes.","18 Years","80 Years",{"count":51,"type":20},216,[23],"This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Asthma is a chronic respiratory disease affecting millions worldwide, and ICS therapy is essential for controlling symptoms and preventing severe exacerbations. However, many patients struggle with adherence, especially those with anxiety about ICS side effects. RAMICS is a multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of personalized telephone-based interventions, including medication education, progressive muscle relaxation (PMR), motivational interviewing (MI), and lung rehabilitation guidance. The study will enroll 216 adult asthma patients with poor ICS adherence and clinically significant anxiety. Participants will be randomized into two groups: the intervention group, receiving weekly telephone sessions, and the control group, receiving standard follow-up calls. The study aims to assess improvements in ICS adherence, reductions in anxiety and depression, better asthma symptom control, and enhanced quality of life. Outcomes will be evaluated immediately after the 8-week intervention and during a 3-month follow-up. By addressing both psychological and medication adherence challenges, this research aims to provide practical solutions for improving asthma management.",[55],"Asthma","2026-06-17",{"date":58,"type":31},"2026-06-18",{"date":60,"type":31},"2024-12-13",{"date":35,"type":20},{"name":37,"class":38},11,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":70,"targetDuration":72,"studyType":73,"phases":4,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100642214","red-dichromatic-imaging-for-improving-post-biopsy-bronchoscopic-field-visibility-100642214","NCT07653945","Red Dichromatic Imaging for Improving Post-Biopsy Bronchoscopic Field Visibility","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Visible abnormal endobronchial lesion under bronchoscopy, including endobronchial neoplasm, mucosal abnormality, airway stenosis, or other lesion requiring biopsy to determine its nature.\n3. Provision of informed consent to participate in this clinical study and signing of the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of contraindications to bronchoscopy, such as severe cardiopulmonary disease, coagulation dysfunction (including patients receiving anticoagulant therapy and\u002For anticoagulant drugs who have not discontinued these drugs for more than 5 days before the examination), poor tolerance of anesthesia, psychiatric disease, or severe neurosis.\n2. Intra-procedural decrease in SpO₂ or inability to tolerate bronchoscopy.\n3. Obvious airway bleeding observed during bronchoscopy that may increase the risk of worsening the patient's condition.\n4. Images that are obviously blurred or out of focus, or that contain severe reflection, bubbles, or instrument obstruction, making subsequent image analysis impossible.\n5. Inability to cooperate with the study for any reason, or any other condition that the investigator considers unsuitable for study participation.",{"count":71,"type":20},206,"6 Months","OBSERVATIONAL","The goal of this observational study is to learn whether red dichromatic imaging (RDI) can help doctors see the bronchoscopic field more clearly after a biopsy. The study will include adults who need a bronchoscopic biopsy because doctors can see an abnormal area inside the airway.During a bronchoscopic biopsy, bleeding can happen after tissue is taken. Blood may cover the biopsy area and make it harder for doctors to see where to continue the procedure.\n\nRDI is an imaging mode that uses special colors of light to help show blood-covered areas more clearly.The main question this study aims to answer is:Does RDI improve visibility of the bronchoscopic field after bleeding caused by bronchoscopic biopsy? Researchers will compare images taken with standard white light imaging and RDI during the same bronchoscopy procedure. Both types of images will be taken after the first biopsy and before any field-clearing treatment is done.\n\nParticipants will have bronchoscopic biopsy as part of their regular medical care, have images taken using standard white light imaging and RDI during the same procedure, have routine follow-up for possible medical problems after bronchoscopy. Taking part in this study will not add extra biopsies or change the participant's regular medical care.",[76,77,78],"Bronchoscopic Biopsy","Airway Lesion","Biopsy-related Bleeding",[80,81,82,83],"Bronchoscopy","Biopsy","Hemorrhage","Optical Imaging","NOT_YET_RECRUITING","2026-06-15",{"date":56,"type":31},{"date":88,"type":20},"2026-07-01",{"date":90,"type":20},"2026-12-31",{"name":37,"class":38},7,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":73,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100643198","effect-of-mycobacterial-infection-on-immune-status-100643198","NCT07638670","Effect of Mycobacterial Infection on Immune Status","EMIIS","Inclusion Criteria and Exclusion Criteria:\n\nInclusion Criteria：\n\n1. Age ≥ 18 years, all genders and races accepted.\n2. Patients with active pulmonary tuberculosis diagnosed clinically or by bronchoscopy within less than 1 week.\n3. Patients with latent tuberculosis infection (positive T-SPOT test but no evidence of active tuberculosis infection).\n4. Patients with tuberculous pleurisy with onset within less than 1 week.\n5. Voluntarily join this study and sign the informed consent form.\n6. Patients whose drug susceptibility test or NGS results indicate resistance to at least isoniazid and rifampicin (MDR-TB).\n7. Patients whose drug susceptibility test or NGS results indicate sensitivity to first-line anti-tuberculosis drugs.\n8. Patients whose drug susceptibility test or NGS results indicate resistance to only one anti-tuberculosis drug.\n9. Patients with newly identified nontuberculous mycobacterial infection (within less than 1 week) by sputum culture or NGS.\n\nExclusion Criteria：\n\n1. Immunosuppressive conditions including HIV infection, long-term use (\\>1 month) of immunosuppressive agents or corticosteroids, severe malnutrition, etc.\n2. Concurrent other lung diseases, severe liver or kidney dysfunction, severe endocrine diseases, hematological diseases, or malignant tumors that may affect the study outcomes.\n3. Patients with diabetes mellitus.\n4. Pregnant or lactating women.\n5. Patients unable or unwilling to provide informed consent, or with poor compliance.",{"count":101,"type":20},120,"60 Days","This study, titled \"Effect of Mycobacterial Infection on Immune Status\" (EMIIS), investigates the immune-driven mechanisms of mycobacterial infections, focusing on the dynamic immune characteristics of multidrug-resistant tuberculosis (MDR-TB), nontuberculous mycobacterial (NTM) infections, and tuberculous pleurisy. Mycobacterial infections (including the Mycobacterium tuberculosis complex and nontuberculous mycobacteria) remain a major global public health threat. EMIIS is a single-center, randomized, single-blind,prospective study. The study recruited 120 participants, divided into groups of healthy individuals\u002Fcommunity-acquired pneumonia patients, active pulmonary tuberculosis patients, latent tuberculosis infection patients, tuberculous pleurisy patients, and nontuberculous mycobacteria patients. Blood samples were collected from all groups within 3 days before treatment and 2-3 months after treatment. Pleural effusion samples were additionally collected from the tuberculous pleurisy group within 3 days before treatment and 2 months after treatment. Exhaled breath condensate (EBC) was collected from the nontuberculous mycobacteria group. Utilizing mass cytometry (CyTOF) and multi-dimensional indicators, the study aims to elucidate the immune-driven mechanisms of mycobacterial infections and provide new strategies for individualized treatment.",[105],"Tuberculosis","2026-06-04",{"date":108,"type":31},"2026-06-10",{"date":110,"type":31},"2025-07-09",{"date":112,"type":20},"2026-07-20",{"name":37,"class":38},1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":126,"conditions":127,"keywords":134,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":114},"100630896","immune-status-and-disease-control-of-inflammatory-airway-diseases-100630896","NCT07493629","Immune Status and Disease Control of Inflammatory Airway Diseases","Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases","ISDC-IAD","Inclusion Criteria\n\n1. Age ≥18 years (≥40 years for COPD patients).\n2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.\n3. PRISm patients (post-BD FEV1\u002FFVC ≥70% and FEV1 \\\u003C80% predicted)\n4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.\n5. Healthy controls: normal lung function, FeNO \\\u003C20 ppb, total IgE \\\u003C100 IU\u002FmL, no chronic disease, smoking \\\u003C10 pack-years, no immunosuppressant use within 3 months.\n\nExclusion Criteria\n\n1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.\n2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.\n3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)\n4. Pregnant or lactating women.\n5. Patients with poor compliance as judged by the investigators.\n6. Subjects currently participating in other clinical studies.",true,{"count":125,"type":20},200,"The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:\n\n1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.\n\nParticipants will:\n\n1. Answer questions about their health and symptoms.\n2. Give blood samples\n3. Have lung function tests and other standard check-ups.\n4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.",[128,129,130,131,132,133],"Airway Inflammation","Chronic Obstructive Pulmonary Disease (COPD)","Asthma (Diagnosis)","Bronchiectasis","OSAS (Obstructive Sleep Apneas Syndrome)","Allergic Bronchopulmonary Aspergillosis (ABPA)",[135,136,137,138,139],"Airway Inflammatory Diseases","Immunophenotyping","Metabolomics","Cytometry by Time-of-Flight","High-dimensional immune profiling","2026-03-23",{"date":142,"type":31},"2026-03-25",{"date":144,"type":31},"2025-08-01",{"date":146,"type":20},"2026-08-01",{"name":37,"class":38},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":164,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":114},"100619696","lidocaine-decreases-postoperative-lung-cancer-reoccurance-and-metatasis-risk-100619696","NCT07347977","Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk","Lidocaine Infusion Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk: a Multicenter Randomized Controlled Study","LidCRM","Inclusion Criteria:\n\n1. Age range: 18-80 years old.\n2. Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer\n3. Is willing and capable of providing consent.\n\nExclusion Criteria:\n\n1. Palliative surgery without intention of cure.\n2. Extensive comorbidities (ASA IV).\n3. Patients with known or suspected allergy to lidocaine.\n4. Patients who are currently pregnant or breastfeeding.\n5. Patients who may experience adverse reactions due to accumulation of lidocaine during intravenous infusion, as stated in the Summary of Product Characteristics (SmPC) for lidocaine.\n6. Currently, there is abnormal liver function, with ALT or AST levels exceeding the laboratory reference range by a factor of 2.\n7. Currently, there is severe renal insufficiency (serum creatinine ≥451umol\u002FL or glomerular filtration rate (calculated using the MDRD formula) \\\u003C30ml\u002Fmin).\n8. Epilepsy.\n9. Patients with cardiac conduction abnormalities, including second-degree or third-degree heart block without a pacemaker, left bundle branch block, sick sinus syndrome, and pre-excitation syndrome (confirmed by medical history and electrocardiogram), as well as those with low cardiac output due to reduced left ventricular ejection fraction.\n10. Concurrent use with continuous infusion of other local anesthetic drugs (such as epidural).\n11. Patients who use drugs that may cause reasons for exclusion, including Class I and Class III antiarrhythmic drugs (such as mexiletine and amiodarone), cimetidine, and antiviral drugs. Eligibility will be determined by local clinicians and verified by clinical trial doctors.\n12. Patients with body weight \\\u003C40kg",{"count":157,"type":20},1400,[23],"The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients.\n\nParticipants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg\u002Fkg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg\u002Fkg\u002Fh (calculated as 1-1.5 mg\u002Fkg\u002Fh in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge",[161,162,163],"Non-Small Cell Lung Cancer","Recurrence","Survival Analysis",[165,166,162,167],"Lidocaine","Non-small cell lung cancer","Survival analysis","2026-01-11",{"date":170,"type":31},"2026-01-16",{"date":172,"type":20},"2026-01-01",{"date":174,"type":20},"2029-12-30",{"name":37,"class":38},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":123,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":183,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":114},"100617075","effects-of-environmental-fungal-exposure-on-bronchial-asthma-abpa-and-bronchiectasis-100617075","NCT07313904","Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis","Effects of Environmental Fungal Exposure on Bronchial Asthma, Allergic Bronchopulmonary Aspergillosis (ABPA), and Bronchiectasis","Inclusion Criteria:\n\n1. Age range of 18-80 years old (including 18 and 80 years old), gender and race are not limited;\n2. No history of asthma, ABPA, or other chronic respiratory diseases.\n3. No history of allergic diseases, such as allergic rhinitis, eczema, or food allergies.\n4. Pulmonary function is normal or close to the normal range.\n5. Laboratory testing:\n\n1\\. Blood routine: High sensitivity C-reactive protein, white blood cells, neutrophils, lymphocytes, and monocytes are all within the normal range.\n\nAllergen testing: IgE levels for common allergens such as dust mites, cat hair, dog hair, cockroaches, mold, and pollen are normal or close to the normal range.\n\nExclusion Criteria:\n\n1. Suffering from bronchial asthma ABPA、 Bronchiectasis or other respiratory diseases: chronic obstructive pulmonary disease, active pulmonary tuberculosis, pulmonary embolism, lung cancer, pneumothorax, hemoptysis, pulmonary arterial hypertension, interstitial lung disease, etc;\n2. Cancer patients who suffer from serious other systemic diseases, such as myocardial infarction, stroke, hypertensive crisis or refractory hypertension, severe arrhythmia, heart failure, aortic aneurysm, liver failure, renal failure, hematological disorders, etc., and have recently been discovered or are currently receiving treatment;\n3. Four weeks prior to enrollment, systemic use of antibiotics, antifungal drugs, immunosuppressants, cytotoxic agents, hormones, etc;\n4. Other individuals with contraindications for induced sputum testing:",{"count":184,"type":20},125,"This study is a prospective, observational study of patients aged 18-80 years with clinical diagnosis of bronchial asthma, allergic bronchopulmonary aspergillosis (ABPA), bronchiectasis and healthy subjects. Among them, the bronchial asthma group will be divided into asthma control group, asthma partial control group and asthma uncontrolled group according to the GINA asthma control classification. Record the baseline information of the subjects in detail, including basic information, disease course, smoking, previous acute attacks and hospitalizations, long-term medication, etc. (including the frequency, dose and duration of ICS use, antifungal drug type, dose, duration of use, and course of treatment), and evaluate and record environmental factors (such as indoor).Humidity, temperature, ventilation, pet keeping, plant planting, etc.) and other lifestyle factors that may affect disease control and fungal exposure. The patient's disease status was assessed using questionnaire scores.\n\nSputum samples were taken at the time of enrollment.Set (asthma ABPA group uses sputum induction), pulmonary function test and bronchodilator test, FeNO measurement (asthma ABPA group only), blood routine test, Aspergillus-specific IgE and IgG detection, total immunoglobulin IgE, allergen detection, etc. Dust was collected indoors (bedrooms), outdoor (balconies) and on the surface of air conditioners or fans (if applicable) in the subject's living environment, and environmental data such as ambient temperature, humidity, and particulate matter concentration were recorded. 18S rRNA technology was used for sputum and dust fungus detection, and ELISA was used for asthmatitis symptomatic markers, which assess the impact of fungal infections on the disease. Follow-up for each subject 6 months, 6 months after enrollment, the patient's symptom changes, acute exacerbations\u002Fexacerbations, and prognosis were recorded, and relevant questionnaire scores were completed.",[187,55,131,188],"Environmental Exposure","ABPA","2025-12-17",{"date":191,"type":31},"2026-01-02",{"date":193,"type":31},"2025-07-23",{"date":195,"type":20},"2026-06-30",{"name":37,"class":38},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100617023","pulsed-field-ablation-for-non-valvular-atrial-fibrillation-after-left-atrial-appendage-occlusion-100617023","NCT07313228","Pulsed Field Ablation for Non-valvular Atrial Fibrillation After Left Atrial Appendage Occlusion","Pulsed Field Ablation of Non-valvular Atrial Fibrillation After Left Atrial Appendage Occlusion: A Prospective, Single-center, Single-arm Clinical Trial","PFA after LAAO","Inclusion Criteria:\n\n1. Aged 18-75 years;\n2. Documented symptomatic atrial fibrillation;\n3. Ineffective or intolerant to at least one class I or III antiarrhythmic drug;\n4. Able to fully understand the treatment protocol, voluntarily sign the informed consent form, and willing to undergo the required examinations, procedures, and follow-up.\n\nExclusion Criteria:\n\n1. Patients who have previously undergone left atrial surgery;\n2. Left atrial thrombus;\n3. Patients with pulmonary agenesis;\n4. Female patients of reproductive age who cannot use effective contraception within 12 months after enrollment;\n5. Left atrial anteroposterior diameter ≥ 55 mm;\n6. Left ventricular ejection fraction (LVEF) ≤ 40%;\n7. Patients who have previously undergone interatrial septal repair or removal of atrial myxoma;\n8. Patients with active implanted devices (e.g., pacemaker, ICD);\n9. Patients with NYHA heart failure class III-IV;\n10. Patients with a clear history of cerebrovascular disease (including cerebral hemorrhage, stroke, or TIA) within the past 6 months;\n11. Patients who have experienced cardiovascular events (e.g., acute myocardial infarction, coronary intervention or bypass surgery, valve replacement or repair, atrial or ventricular surgery) within the past 3 months;\n12. Patients with acute or severe systemic infections;\n13. Patients with severe liver or kidney disease, malignancy, or end-stage disease that may affect the treatment, assessment, or compliance of the trial (as judged by the investigator);\n14. Patients with significant bleeding tendency, hypercoagulable state, or severe hematologic disorders;\n15. Patients who have participated or are currently participating in another clinical trial within the past 12 months prior to enrollment;\n16. Patients who the investigator deems unsuitable for participation in this trial.","75 Years",{"count":207,"type":20},70,"This is a single-center, prospective, single-arm clinical trial designed to evaluate the safety and efficacy of pulsed field ablation (PFA) after left atrial appendage occlusion (LAAO) in patients with non-valvular atrial fibrillation (AF). The trial will include patients who have undergone successful LAAO and have symptomatic AF that is refractory to or intolerant of class I or III antiarrhythmic drugs. The primary objective is to assess the effectiveness of PFA in preventing AF recurrence and its safety, including the occurrence of serious adverse events. Patients will be followed up for 12 months post-procedure to evaluate outcomes such as recurrence of AF, complications, and device-related issues.",[210,211,212],"Atrial Fibrillation","Left Atrial Appendage Occlusion","Pulsed Field Ablation",[210,214,215],"left atrial appendage occlusion","pulsed field ablation",{"date":217,"type":31},"2025-12-31",{"date":219,"type":20},"2025-12",{"date":221,"type":20},"2027-06",{"name":37,"class":38},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":114},"100606156","development-and-validation-of-a-risk-prediction-model-for-ischemic-stroke-in-acute-myocardial-infarction-without-comorbid-atrial-fibrillation-100606156","NCT07171892","Development and Validation of a Risk Prediction Model for Ischemic Stroke in Acute Myocardial Infarction Without Comorbid Atrial Fibrillation","Inclusion Criteria:\n\n* myocardial infarction without atrial fibrillation\n\nExclusion Criteria:\n\n* Thrombophilia\n* Paradoxical Embolism through a Patent Foramen Ovale (PFO)\n* Iatrogenic embolism\n* Coronary slow-flow phenomenon\n* Coronary vasospasm\n* Dissection,",{"count":230,"type":20},4000,"Study Goal:\n\nThis observational study aims to develop a tool to predict the risk of ischemic stroke(stroke caused by a blood clot) in people who survive a heart attack and do not have irregular heartbeats (atrial fibrillation) .\n\nKey Questions:\n\nCan we create an accurate tool using existing hospital records to identify which heart attack survivors without irregular heartbeats have the highest risk of stroke while still in the hospital? Can this tool reliably predict stroke risk at 3 months and 1 year after leaving the hospital?\n\nAbout Participation:\n\nThis study will only use information from past patient medical records. If you had a heart attack and were treated at our hospital between January 1, 2014, and December 31, 2023 , and you did not have irregular heartbeats (atrial fibrillation), your anonymous health information might be included in this analysis.\n\nNo new patients are being recruited. This study analyzes existing information only.\n\nNo one will be asked to do anything new. We will not contact patients directly.\n\nWhat Information Will Be Used?\n\nResearchers will securely review past hospital records to look at information doctors usually collect during heart attack care, such as:\n\nYour age and medical history (like previous strokes, diabetes, high blood pressure, kidney problems).\n\nTest results (like heart pumping strength). Treatment details after your heart attack. Information on whether you had a stroke later. All personal details (like name, ID number) will be permanently removed to protect privacy.\n\nWhy This Matters:\n\nPeople who survive a heart attack have a higher risk of stroke later, even without the common irregular heartbeat condition. A stroke can be life-threatening or seriously impact quality of life. This tool aims to help doctors in the future better understand a patient's individual stroke risk after a heart attack, so preventative steps can be discussed if needed.\n\nEthics \\& Safety:\n\nApproved: This study has been reviewed and approved by our hospital's Ethics Committee to ensure it is safe and ethical.\n\nPrivacy Guaranteed: Your personal identity is protected. All data is stored securely on the hospital's protected network with strict access controls. No personal information leaves the hospital.\n\nResearcher Note:\n\nThis tool is currently for research purposes only. It will not be used for your medical care right now.\n\nIf doctors want to use this tool in future clinical practice, a new study directly involving patients with their informed consent would be required.",[233],"Myocardial Infarction",[235],"Clinical Prediction Model","2025-09-10",{"date":238,"type":31},"2025-09-15",{"date":240,"type":20},"2025-10-21",{"date":242,"type":20},"2025-11-30",{"name":37,"class":38},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":251,"targetDuration":4,"studyType":73,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100588178","respiratory-microbiota-infection-characteristics-and-imaging-manifestations-in-patients-with-chronic-airway-inflammation-100588178","NCT06938022","Respiratory Microbiota, Infection Characteristics and Imaging Manifestations in Patients With Chronic Airway Inflammation","Chronic Airway Inflammation: The Impact of Respiratory Microbiota, Infection Characteristics, and Imaging Features on Disease Progression and Quality of Life-A Multomic and Comprehensive Study","Inclusion Criteria:\n\n(1) Age: 18 to 80 years old (inclusive), without restrictions on gender or ethnicity.\n\n(2) Disease Diagnosis:\n\n1. COPD patients must meet the GOLD diagnostic criteria, with post-bronchodilator FEV1\u002FFVC \\\u003C 70% and FEV1 \\\u003C 80% of the predicted value.\n2. Asthma patients must meet clinical diagnostic criteria, including recurrent wheezing, shortness of breath symptoms, frequently occurring at night; during attacks, wheezing sounds can be heard in both lungs; effective treatment with bronchodilators or corticosteroids, or symptoms can be relieved spontaneously, and at least one of the following tests must be positive: positive bronchial provocation test; positive bronchodilator test with FEV1 increase ≥12%, and FEV1 increase absolute value ≥200ml; daily peak expiratory flow (PEF) variability ≥10% within one week.\n3. Bronchiectasis patients must meet the diagnostic criteria based on CT imaging, including: bronchial diameter\u002Faccompanying pulmonary artery diameter ratio \\>1; high-resolution CT (HRCT) showing dilated cystic, columnar, or cystic bronchial shadows.\n\n(3) Disease Status:\n\n1. Patients with chronic airway inflammation must be in a stable phase, defined as no acute exacerbations, hospitalizations, or use of other treatments for at least 4 weeks.\n2. COPD patients with acute exacerbations must meet the definition of acute exacerbation: at least two major symptoms (dyspnea, increased sputum, and purulent sputum) worsen, or at least one major symptom and one minor symptom (wheezing, sore throat, cough without other causes, and fever) worsen.\n3. Asthma patients in the acute attack phase must meet the definition of acute attack: sudden worsening of symptoms (including wheezing, shortness of breath, chest tightness, cough, etc.), decreased lung function, poor response to routine treatment, other clinically diagnosed acute attacks.\n4. Bronchiectasis patients with acute exacerbations must meet the definition of acute exacerbation: increased cough, increased sputum or sputum viscosity, purulent sputum, dyspnea or decreased exercise tolerance, fatigue or discomfort, hemoptysis, at least three of the above six symptoms occur newly or significantly worsen, lasting ≥48 hours.\n\n(4) Treatment Status:\n\n1. In the chronic airway inflammation patient ICS treatment study, patients must require ICS treatment under routine care, i.e., have been recommended to use ICS and are currently using ICS treatment.\n2. In other studies, patients must maintain unchanged long-term medication during the follow-up period, but may be appropriately adjusted according to the attending physician's clinical decision.\n\n(5) Others:\n\n1. All participants must voluntarily participate in the study and sign the informed consent form.\n2. Patients must be able to communicate in language or writing, understand and sign the content of the informed consent form, and be able to complete the required pulmonary function and other auxiliary examinations for the trial.\n\nExclusion Criteria:\n\n(1) Recent Medication Use:\n\n1. In the chronic airway inflammation patient ICS study, exclude patients who have used corticosteroid-related treatment within the last 3 months, exclude patients who have received antibiotic treatment within the last 3 months.\n2. In other studies, exclude patients who have used antibiotics, immunosuppressants, cytotoxic agents, or hormones systemically within the last 4 weeks.\n\n(2) Other Significant Diseases:\n\n1. Clinically significant pulmonary diseases other than the study disease, such as active tuberculosis, pulmonary embolism, pneumothorax, pneumothorax, pulmonary hypertension, interstitial lung disease, lung cancer, pulmonary fibrosis, tuberculosis, etc.\n2. Severe other systemic diseases, such as myocardial infarction, severe arrhythmia, liver dysfunction, renal insufficiency, rheumatic immune system diseases, hematological diseases, active malignant tumors, etc.\n\n(3) Disease Status:\n\n\\[1\\] Patients who have experienced any degree of acute exacerbation within the last 4 weeks before screening for the stable phase study.\n\n(4) Special Populations:\n\n1. Female patients who are pregnant or breastfeeding.\n2. Patients with poor compliance.\n3. Patients who cannot complete sample collection due to physical or psychological factors, especially those who need to collect multiple samples.\n4. Patients who are participating in other clinical trials. (5) Related Contraindications:\n\n\\[1\\] Patients with contraindications to pulmonary function tests and chest CT, such as chest metal, history of myocardial infarction, stroke, aortic aneurysm, or ocular surgery or retinal detachment within the last 3 months.",{"count":252,"type":20},1000,"This study，Respiratory microbiota, infection characteristics and imaging manifestations in patients with chronic airway inflammation， adopted a prospective, observational, multi-omics study design to comprehensively evaluate the effects of respiratory microbiota, infection characteristics and imaging manifestations on disease outcomes and quality of life in patients with chronic airway inflammation. Involving six parallel sub-studies, These include: (1) the differences and mechanisms of lung microecology in ICS treatment sensitivity and resistance in patients with chronic airway inflammation, (2) the study of respiratory viral infection and inflammatory markers in patients with acute exacerbation of chronic obstructive pulmonary disease, (3) the effect of respiratory viral infection on the airway inflammation and disease severity of asthma in acute exacerbation, (4) the clinical significance of fungal infection in acute exacerbation of bronchiectasis, (5) the role of pulmonary function test and chest CT in predicting acute exacerbation of chronic obstructive pulmonary disease, and (6) the predictive value of baseline pulmonary function and radiomics in acute exacerbation of bronchiectasis， Each sub-study targeted a different study purpose and a specific patient population. All sub-studies followed uniform research principles, including scientificity, ethics, and consistency. All subjects were required to sign an informed consent form before enrollment to ensure that they understood the purpose, process, possible risks and privacy protection measures of the study. The study plans to enroll about 1,000 eligible patients covering chronic airway inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis.\n\nIn this study, multi-omics techniques, including microbiome, metabolomics, radiomics, and transcriptomics, were used to comprehensively evaluate the effects of respiratory microbiota, infection characteristics, and imaging manifestations on disease outcomes and quality of life in patients with chronic airway inflammation.",[255,55,256,131],"Chronic Airway Inflammation","Chronic Obstructive Pulmonary Disease","2025-04-14",{"date":259,"type":31},"2025-04-22",{"date":261,"type":20},"2025-04-15",{"date":263,"type":20},"2027-05-30",{"name":37,"class":38},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":272,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":114},"100574802","phase-2-chir-therapy-for-elderly-dlbcl-intolerant-to-chemo-100574802","NCT06764017","CHiR Therapy for Elderly DLBCL Intolerant to Chemo","A Single-arm, Multicenter, Prospective Clinical Study of CHiR (chidamide, Zanubrutinib, and Lenalidomide) for Newly Diagnosed MYC- and BCL2-positive Diffuse Large B-cell Lymphoma (DLBCL) in Elderly Patients Intolerant to Chemotherapy.","Inclusion Criteria：\n\n1. Age ≥ 70 years;\n2. ECOG score of 0-3;\n3. Rated as unfit or frail on the simplified geriatric assessment (sGA);\n4. Histologically confirmed CD20-positive diffuse large B-cell lymphoma (diagnostic criteria according to WHO 2016), excluding transformed type 2 DLBCL;\n5. Immunohistochemically confirmed positive expression of MYC and BCL2 (MYC ≥ 40%, BCL2 ≥ 50% by immunohistochemistry);\n6. Previously untreated patients;\n7. Cardiac, hepatic, and renal function: creatinine \\\u003C 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase)\u002FAST (aspartate aminotransferase) \\\u003C 2.5 ULN; total bilirubin \\\u003C 2 ULN;\n8. At least one measurable lesion;\n9. Unable to tolerate standard CHOP regimen chemotherapy or unwilling to receive chemotherapy;\n10. Adequate understanding and voluntary signing of the informed consent form. Exclusion Criteria：\n\n1.Patients with central nervous system involvement at the time of onset; 2.Known human immunodeficiency virus (HIV) infection; 3.Pregnant or lactating women; 4.Other tumors requiring treatment; 5.Uncontrollable active infection; 6.Active hepatitis with HBV-DNA copy number not controlled within 2\\*1000\u002FmL despite antiviral treatment; 7.Inability to understand, comply with the study protocol, or sign the informed consent form.","70 Years","100 Years",{"count":275,"type":20},30,[277],"PHASE2","The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.",[280],"Diffuse Large B-Cell Lymphoma",[282,283,284,285,286,287],"diffuse large B-cell lymphoma","MYC- and BCL2-positive","chidamide","zanubrutinib","lenalidomide","elderly patients","2025-03-16",{"date":290,"type":31},"2025-03-19",{"date":292,"type":31},"2025-02-01",{"date":294,"type":20},"2027-08-01",{"name":37,"class":38},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":272,"maxAge":273,"enrollmentInfo":304,"targetDuration":4,"studyType":21,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":320,"locationsCount":114},"100574342","phase-2-clinical-study-of-hirx-therapy-for-newly-diagnosed-elderly-patients-with-dlbcl-intolerant-to-chemotherapy-100574342","NCT06758037","Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy","A Single-arm, Multicenter Phase II Clinical Study of HiR+X Therapy for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) in Elderly Patients Intolerant to Chemotherapy, Guided by Molecular Subtyping and Clinical Characteristics.","HiR+X","Inclusion Criteria:\n\n1. Age ≥ 70 years;\n2. ECOG score 0-3;\n3. Rated as \"unfit\" or \"frail\" on the simplified geriatric assessment (sGA);\n4. Histologically confirmed CD20-positive diffuse large B-cell lymphoma \\[diagnostic criteria according to WHO 2016\\], excluding transformed type 2 DLBCL;\n5. Previously untreated, newly diagnosed patients;\n6. Cardiac, hepatic, and renal function: creatinine \\\u003C 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase) \u002F AST (aspartate aminotransferase) \\\u003C 2.5 x ULN; total bilirubin \\\u003C 2 x ULN;\n7. At least one measurable lesion;\n8. Intolerance to standard CHOP chemotherapy regimen or unwillingness to receive chemotherapy;\n9. Sufficient understanding and voluntary signing of the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with central nervous system involvement at the onset of the disease;\n2. Known human immunodeficiency virus (HIV) infection;\n3. Pregnant or lactating women;\n4. Other tumors requiring treatment;\n5. Uncontrolled active infection;\n6. Active hepatitis with HBV-DNA copy number unable to be controlled within 2000\u002FmL despite antiviral treatment;\n7. Individuals who cannot understand, comply with the study protocol, or sign the informed consent form.",{"count":305,"type":20},50,[277],"To explore the application of HiR (Zebtorizumab, Lenalidomide) + X (targeted drug) guided by NGS molecular typing, the aim is to assess the therapeutic efficacy and safety in newly diagnosed unfit or frail elderly patients with DLBCL aged ≥70 years, and to investigate the genetic subtypes that may benefit from HiR-X.",[309,280],"DLBCL",[309,311,312,313,314],"genetic subtypes","Zebtorizumab","Lenalidomide","unfit",{"date":316,"type":31},"2025-03-18",{"date":318,"type":31},"2025-01-15",{"date":35,"type":20},{"name":37,"class":38},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":205,"enrollmentInfo":327,"targetDuration":328,"studyType":73,"phases":4,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":343,"locationsCount":4},"100574299","a-clinical-study-on-the-combination-of-mitoxantrone-liposome-injection-bendamustine-etoposide-and-cytarabine-for-pretreatment-of-autologous-hematopoietic-stem-cell-transplantation-in-patients-with-lymphoma-100574299","NCT06757478","A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma","Inclusion Criteria:\n\n* 1\\. The patients voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with the follow-up; 2. Patients with histologically or pathologically confirmed non-Hodgkin lymphoma or malignant lymphoma, regardless of gender, 18 to 75 years of age (including the upper limit), are scheduled to undergo autologous hematopoietic stem cell transplantation; 3. Physical status of the Eastern Cancer Collaboration Group (ECOG) : the score was 0\\~2, and the expected survival time was more than 3 months; 4. Patients judged by researchers to be suitable for stem cell transplantation:\n\n  1. Consolidation therapy after first-line induction chemotherapy for aggressive non-Hodgkin lymphoma with poor prognostic factors;\n  2. It is suitable for salvage treatment of chemotherapy-sensitive non-Hodgkin lymphoma after recurrence;\n  3. and salvage treatment of relapsed or primary refractory Hodgkin lymphoma that is sensitive to chemotherapy.\n\n  5\\. The main organs function normally, the specific criteria are as follows:\n  1. Bone marrow hematopoietic function is basically normal, blood routine: WBC ≥ 2.0×10\\^9\u002FL, ANC ≥ 1.0×10\\^9\u002FL, PLT ≥50×10\\^9\u002FL, Hb ≥ 80 g\u002FL. If the peripheral blood indexes were abnormal due to lymphoma invading bone marrow or spleen, the researchers could determine whether the patients were suitable for inclusion.\n  2. Lung function: forced expiratory volume in one second (FEV1) ≥60%, carbon monoxide dispersion (DLCO) ≥50%;\n  3. Liver function: total bilirubin, ALT and AST \\\u003C2×ULN (upper limit of normal); AST and ALT≤3 times the upper limit of normal (ULN), total bilirubin (TBIL) ≤1.5×ULN (if there is liver invasion, AST and ALT≤5×ULN are allowed);\n  4. Renal function: serum creatinine ≤1.5×ULN, creatinine clearance (CrCl) ≥ 60 ml\u002Fmin (calculated according to Cockcroft-Gault formula). Male subjects: CLcr =\\[(140- age (years) x body weight (kg)) \u002F\\[72 x serum creatinine (mg\u002FdL)\\]; Female subjects: CLcr=0.85× CLcr of male subjects;\n  5. Coagulation function: International standardized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n  6. Normal cardiac function: echocardiography or nuclide cardiac function test showed LVEF ≥ 55%, no uncontrolled tachycardia or Tachycardia syndrome, normal or abnormal ECG examination had no clinical significance, myocardial enzyme spectrum CK-MB was normal, pro-BNP was less than 900 pg\u002Fml.\n\n  6\\. Sufficient autologous hematopoietic stem cells have been assessed and collected by researchers: CD34≥2×106\u002FKg; 7. The women were not lactating, were not pregnant, and the female subjects with reproductive capacity were tested for serum pregnancy within 2 weeks before enrollment Test negative and agree not to become pregnant during the study period and for 36 months thereafter; Fertile male or female subjects must use a highly effective contraceptive method throughout the trial and for 1 year after the transplant.\n\nExclusion Criteria:\n\n* 1\\. Received doxorubicin or anthracycline treatment in the past, and the total cumulative dose of doxorubicin was \\> 360 mg\u002Fm² (1 mg doxorubicin is equivalent to 2 mg epirubicin for other anthracycline drugs).\n\n  2\\. Hypersensitivity to any investigational drug or its ingredients. 3. Cardiac function and disease consistent with one of the following conditions: a. Long QTc syndrome or QTc interval \\>480 ms; b. Complete left bundle branch block, degree II or III atrioventricular block; c. Severe, uncontrolled arrhythmias requiring medical treatment; d. New York College of Cardiology Grade ≥ III; e. Cardiac ejection fraction (LVEF) less than 50%; f. A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities within the 6 months prior to recruitment.\n\n  4\\. Hepatitis B, hepatitis C active infection (hepatitis B virus surface antigen or core antibody positive and hepatitis B virus DNA ultra Over 1×10³ copy \u002FmL; More than 1×10³ copies \u002FmL of HCV RNA). 5. Human immunodeficiency virus (HIV) infection (HIV antibody positive). 6. Previous or current co-occurrence of other malignancies (with the exception of malignancies with no known active disease occurring for ≥5 years prior to enrollment that have been treated for the purpose of cure); Basal cell carcinoma of the skin that has been adequately treated and shows no signs of disease (except melanoma); Well-treated carcinoma in situ of the cervix with no signs of disease).\n\n  7\\. Have primary or secondary central nervous system (CNS) lymphoma or have a history of CNS lymphoma.\n\n  8\\. Pregnant and lactating women and patients of childbearing age who do not want to take contraceptive measures.\n\n  9\\. Patients who cannot collect CD34 + hematopoietic stem cells in quantities greater than or equal to 2×10\\^6\u002Fkg.\n\n  10\\. Patients who have previously received solid organ transplants. 11. Patients who have received secondary or higher surgery within three weeks prior to treatment.\n\n  12\\. Serious and active infectious diseases requiring systemic antibiotics, antifungal drugs, and antiviral treatment were present within 15 days prior to transplantation.\n\n  13\\. People with a history of drug abuse (non-medical use of narcotic drugs or psychotropic drugs) or dependence on drugs (sedatives, hypnotics, analgesics, narcotics, stimulants and psychotropic drugs, etc.).\n\n  14\\. Have a history of severe neurological or mental illness, including dementia or epilepsy.\n\n  15\\. History of mental illness or cognitive impairment. 16. Patients deemed unsuitable for enrollment by the investigator.",{"count":275,"type":20},"1 Month","This is a single-arm, open, single-center clinical study. Patients with lymphoma who were to undergo autologous hematopoietic stem cell transplantation were pretreated with mitoxantrone hydrochloride liposome injection combined with standard doses of bendamustine, etoposide, and cytarabine before transplantation, in order to explore the safety and efficacy of this combined pretreatment regimen.\n\nTests were performed during the study to observe efficacy, safety, and tolerability. The treatment period was from pre-treatment to +28 days after transplantation and +28 days after stem cells were transfused. The follow-up period was followed up once a month for 6 months, every 3 months for 6 months to 2 years, and every 6 months for 2 years to 3 years after stem cell reinfusion. All subjects underwent protocol-mandated examinations during treatment to observe safety, tolerability, and efficacy.",[331],"Lymphoma Patient",[333,334,335,336,337,338],"Mitoxantrone hydrochloride liposome","bendamustine","etoposide","cytarabine","HSCT","lymphoma",{"date":316,"type":31},{"date":341,"type":20},"2025-05-01",{"date":35,"type":20},{"name":37,"class":38},{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":352,"targetDuration":4,"studyType":21,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":114},"100572531","effectiveness-and-safety-of-sodium-bicarbonate-pleural-lavage-in-the-treatment-of-complex-pleural-effusion-100572531","NCT06734481","Effectiveness and Safety of Sodium Bicarbonate Pleural Lavage in the Treatment of Complex Pleural Effusion","Effectiveness and Safety of Sodium Bicarbonate Pleural Lavage in the Treatment of Complex Pleural Effusion: Protocol for a Multicenter Randomized Controlled Trial（SAPLIC Study）","SAPLIC","Inclusion Criteria:\n\n* Hospitalized patients aged 18 to 80 years, inclusive.\n* Patients fulfilling any one of the following three criteria for complicated pleural effusion: A. Pleural fluid pH \\\u003C 7.2; B. Pleural fluid glucose \\\u003C 2.2 mmol\u002FL and LDH \\> 1000 IU\u002FL; C. Positive pleural fluid culture or smear for pathogens.\n* Pleural effusion volume exceeding 300 mL, as determined by CT imaging using the formula D\\^2 \\* L (where D represents the maximum depth and L the maximum length), and for whom pleural effusion drainage is clinically indicated according to established guidelines or criteria.\n\nExclusion Criteria:\n\n* Patients with known allergies to sodium bicarbonate or normal saline.\n* Patients with severe coagulation disorders.\n* Patients with severe heart or kidney failure.\n* Pregnant or lactating women.\n* Patients with pleural effusion caused by hospital-acquired interference, tuberculosis, fungal infections, or non-infectious causes.\n* Patients unable to tolerate intrapleural administration.\n* Patients with chronic lung diseases that may affect antibiotic efficacy, such as uncontrolled chronic obstructive pulmonary disease (COPD GOLD E group), bronchiectasis, or immunodeficiency.\n* Patients who have experienced shock, major bleeding, trauma, or pulmonary surgery within the past 5 days.\n* Patients with a history of lung or pleural surgery on the side of the pleural effusion.\n* Patients who have recently had chest tubes placed due to pneumothorax, surgery, or pleural effusion.\n* Patients currently enrolled in another drug or device clinical trial.\n* Patients with poor compliance or difficulty in follow-up, or those with an expected survival of less than 3 months due to conditions other than pleural effusion.",{"count":353,"type":20},260,[23],"The goal of this clinical trial is to evaluate the safety and efficacy of sodium bicarbonate pleural lavage in treating complex pleural effusion in adult. The main questions it aims to answer are:\n\nWill sodium bicarbonate pleural lavage reduce the failure rate of medical treatment (referral rate for surgery) for complicated pleural effusion？ Can sodium bicarbonate pleural lavage accelerating the rehabilitation of patients with complicated pleural effusion？ Will sodium bicarbonate pleural lavage improve the prognosis of patients with complicated pleural effusion?\n\nParticipants will will undergo catheter placement for continuous drainage of pleural effusion. Once at least 200 mL of pleural effusion has been drained:\n\nGroup A: Participants will receive a daily intrapleural injection of 200 mL of saline in 7 days; Group B: Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days.",[357],"Complicated Pleural Effusion\u002F Empyema","2024-12-12",{"date":360,"type":31},"2024-12-16",{"date":362,"type":31},"2024-04-01",{"date":146,"type":20},{"name":37,"class":38},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":374,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":114},"100571907","value-of-bronchoalveolar-lavage-with-acetylcysteine-in-the-treatment-of-bronchiectasis-100571907","NCT06726356","Value of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis.","Efficacy and Safety of Bronchoalveolar Lavage with Acetylcysteine in the Treatment of Bronchiectasis with Infection in Adults: a Multicentre, Blinded, Randomised Controlled Study.","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years;\n2. Chest CT suggestive of bronchiectasis;\n3. meet the criteria for an acute exacerbation of bronchiectasis with symptoms such as cough, sputum, chest tightness or wheezing, and c. Patients who meet the criteria for an acute exacerbation of bronchiectasis with symptoms of cough, sputum, chest tightness or wheezing and who consent to bronchoscopy with bronchoalveolar lavage\n4. patients who agreed to participate in the study and signed an informed consent form;\n\nExclusion Criteria:\n\n1. Severe cardiopulmonary diseases, coagulation disorders, poor tolerance to anaesthesia, psychiatric disorders or severe neuroses that are contraindications to bronchoscopy;\n2. Intraoperative findings of decreased SPO2 or inability to tolerate bronchoscopy or inability to tolerate further bronchoalveolar lavage;\n3. Inability to co-operate with the study for any reason or in the opinion of the investigator, inappropriate for inclusion in the study for other reasons;\n4. Bronchoscopy of patients with significant intra-airway haemorrhage who may be at risk of exacerbation due to bronchoalveolar lavage;\n5. Patients with acetylcysteine allergy;\n6. Missing information;",{"count":373,"type":20},180,[23],"Bronchiectasis is a clinical syndrome characterised by chronic cough, profuse sputum and\u002For intermittent haemoptysis, with or without shortness of breath and respiratory failure of varying severity, and abnormal thickening and dilatation of the bronchial walls as seen on lung imaging. Nebulised inhalation of N-acetylcysteine has been shown to significantly improve symptoms, shorten the length of hospital stay, reduce the rate of re-hospitalisation within six months, and improve lung function in patients with bronchiectasis with a high degree of safety. There have been no studies on the efficacy and safety of bronchoscopic irrigation with N-acetylcysteine solution in the treatment of bronchiectasis. The aim of this study was to investigate whether bronchoscopic acetylcysteine lavage combined with conventional treatment is more beneficial to patients with bronchiectasis than conventional treatment combined with conventional bronchoalveolar lavage and conventional treatment without bronchoscopy, respectively.",[377],"Bronchiectasis with Acute Exacerbation",[379],"bronchiectasis; acetylcysteine; bronchoalveolar lavage; Bronchoscopic airway clearance therapy","2024-12-09",{"date":382,"type":31},"2024-12-10",{"date":384,"type":31},"2024-08-14",{"date":386,"type":20},"2026-07-30",{"name":37,"class":38},""]